OBJECTIVE: To assess the psychometric performance of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life Questionnaire (UFS-QoL), a patient measure of the severity of uterine fibroid (UF) symptoms and their impact on health-related quality of life (HRQL). METHODS: This was a retrospective analysis of phase 2a data from pre-menopausal women with heavy menstrual bleeding associated with UF. Participants completed the UFS-QoL at Baseline, Treatment Month 3, and Follow-up Month 3 and a daily diary with a Menstrual Bleeding Scale and the UF Daily Symptom Scale throughout the study duration. Descriptive statistics were performed on patient demographic characteristics; analyses were conducted to assess the internal consistency reliability, validity, and responsiveness of the UFS-QoL 4 week recall version. RESULTS: A total of 271 women were enrolled with a mean age of 41.8 years; 74% were black. The UFS-QoL demonstrated excellent internal consistency reliability, with Cronbach's alpha coefficient values >0.70 for each subscale at each study visit. Results indicated good concurrent validity with the UF Daily Symptom Scale items. The women with amenorrhea at Treatment Month 3 had significantly better scores on all UFS-QoL subscales and HRQL Total than women with menstrual bleeding, indicating acceptable discriminant validity. Mean subscale change scores from Baseline to Treatment Month 3 were 19.2 to 39.8. Effect sizes were moderate to large (0.53 to 1.86), demonstrating responsiveness to change. LIMITATIONS: As this study is a post hoc validation of the 4 week recall UFS-QOL, it is limited to the clinical trial data available and does not include a direct comparison to the 3 month recall version of UFS-QOL. CONCLUSIONS: The 4 week recall version of the UFS-QoL demonstrated good internal consistency reliability, concurrent validity, and responsiveness and is psychometrically comparable to the original 3 month recall UFS-QoL. CLINICAL TRIAL REGISTRATION: Data from a phase 2a, cohort design proof of concept study (trial M12-663); ClinicalTrials.gov identifier NCT01441635. Date of Registration: 6 September 2011.
OBJECTIVE: To assess the psychometric performance of the 4 week recall version of the Uterine Fibroid Symptom and Health-related Quality of Life Questionnaire (UFS-QoL), a patient measure of the severity of uterine fibroid (UF) symptoms and their impact on health-related quality of life (HRQL). METHODS: This was a retrospective analysis of phase 2a data from pre-menopausal women with heavy menstrual bleeding associated with UF. Participants completed the UFS-QoL at Baseline, Treatment Month 3, and Follow-up Month 3 and a daily diary with a Menstrual Bleeding Scale and the UF Daily Symptom Scale throughout the study duration. Descriptive statistics were performed on patient demographic characteristics; analyses were conducted to assess the internal consistency reliability, validity, and responsiveness of the UFS-QoL 4 week recall version. RESULTS: A total of 271 women were enrolled with a mean age of 41.8 years; 74% were black. The UFS-QoL demonstrated excellent internal consistency reliability, with Cronbach's alpha coefficient values >0.70 for each subscale at each study visit. Results indicated good concurrent validity with the UF Daily Symptom Scale items. The women with amenorrhea at Treatment Month 3 had significantly better scores on all UFS-QoL subscales and HRQL Total than women with menstrual bleeding, indicating acceptable discriminant validity. Mean subscale change scores from Baseline to Treatment Month 3 were 19.2 to 39.8. Effect sizes were moderate to large (0.53 to 1.86), demonstrating responsiveness to change. LIMITATIONS: As this study is a post hoc validation of the 4 week recall UFS-QOL, it is limited to the clinical trial data available and does not include a direct comparison to the 3 month recall version of UFS-QOL. CONCLUSIONS: The 4 week recall version of the UFS-QoL demonstrated good internal consistency reliability, concurrent validity, and responsiveness and is psychometrically comparable to the original 3 month recall UFS-QoL. CLINICAL TRIAL REGISTRATION: Data from a phase 2a, cohort design proof of concept study (trial M12-663); ClinicalTrials.gov identifier NCT01441635. Date of Registration: 6 September 2011.
Authors: Erica E Marsh; Ayman Al-Hendy; Dale Kappus; Alex Galitsky; Elizabeth A Stewart; Majid Kerolous Journal: J Womens Health (Larchmt) Date: 2018-09-19 Impact factor: 2.681
Authors: Bruce R Carr; Elizabeth A Stewart; David F Archer; Ayman Al-Hendy; Linda Bradley; Nelson B Watts; Michael P Diamond; Jingjing Gao; Charlotte D Owens; Kristof Chwalisz; W Rachel Duan; Ahmed M Soliman; Matthew B Dufek; James A Simon Journal: Obstet Gynecol Date: 2018-11 Impact factor: 7.661
Authors: Henry A Glick; Taiga Miyazaki; Katsuji Hirano; Elisa Gonzalez; Luis Jodar; Bradford D Gessner; Raul E Isturiz; Adriano Arguedas; Shigeru Kohno; Jose A Suaya Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079
Authors: Andrea S Lukes; David Soper; Amanda Harrington; Vilma Sniukiene; Yifan Mo; Patrick Gillard; Lee Shulman Journal: Obstet Gynecol Date: 2019-05 Impact factor: 7.661
Authors: Manuela Neri; Gian Benedetto Melis; Elena Giancane; Valerio Vallerino; Monica Pilloni; Bruno Piras; Alessandro Loddo; Anna Maria Paoletti; Valerio Mais Journal: Int J Womens Health Date: 2019-10-22
Authors: James A Simon; Ayman Al-Hendy; David F Archer; Kurt T Barnhart; Linda D Bradley; Bruce R Carr; Thomas Dayspring; Eve C Feinberg; Veronica Gillispie; Sandra Hurtado; JinHee Kim; Ran Liu; Charlotte D Owens; Ozgul Muneyyirci-Delale; Alice Wang; Nelson B Watts; William D Schlaff Journal: Obstet Gynecol Date: 2020-06 Impact factor: 7.623
Authors: Ayman Al-Hendy; Linda Bradley; Charlotte D Owens; Hui Wang; Kurt T Barnhart; Eve Feinberg; William D Schlaff; Elizabeth E Puscheck; Alice Wang; Veronica Gillispie; Sandra Hurtado; Ozgul Muneyyirci-Delale; David F Archer; Bruce R Carr; James A Simon; Elizabeth A Stewart Journal: Am J Obstet Gynecol Date: 2020-07-20 Impact factor: 8.661